{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T07:16:00Z","timestamp":1782544560331,"version":"3.54.5"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30AI168436"],"award-info":[{"award-number":["P30AI168436"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tuberculosis Research Advancement Center","award":["P30AI094189"],"award-info":[{"award-number":["P30AI094189"]}]},{"DOI":"10.13039\/100007813","name":"Center for AIDS Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007813","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The provision of tuberculosis-preventive therapy (TPT) to vulnerable populations is critical for global control. Shorter-course TPT regimens are highly effective and improve completion rates. Despite incorporation of 1 month of rifapentine and isoniazid into global guidelines, current US TPT guidelines do not include this as a recommended regimen, but should.<\/jats:p>","DOI":"10.1093\/cid\/ciad659","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T21:10:45Z","timestamp":1698268245000},"page":"514-517","source":"Crossref","is-referenced-by-count":4,"title":["US Guidelines Fall Short on Short-Course Tuberculosis-Preventive Therapy"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5765-3913","authenticated-orcid":false,"given":"Sonya","family":"Krishnan","sequence":"first","affiliation":[{"name":"Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4710-925X","authenticated-orcid":false,"given":"Richard E","family":"Chaisson","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"2024032020271949300_ciad659-B1","doi-asserted-by":"crossref","first-page":"1900655","DOI":"10.1183\/13993003.00655-2019","article-title":"The global prevalence of latent tuberculosis: a systematic review and meta-analysis","volume":"54","author":"Cohen","year":"2019","journal-title":"Eur Respir J"},{"key":"2024032020271949300_ciad659-B2","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.3201\/eid2410.180716","article-title":"Simple estimates for local prevalence of latent tuberculosis infection, United States, 2011\u20132015","volume":"24","author":"Haddad","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"2024032020271949300_ciad659-B3","doi-asserted-by":"crossref","first-page":"e0140881","DOI":"10.1371\/journal.pone.0140881","article-title":"Tuberculosis infection in the United States: prevalence estimates from the National Health and Nutrition Examination Survey, 2011\u20132012","volume":"10","author":"Miramontes","year":"2015","journal-title":"PLoS One"},{"key":"2024032020271949300_ciad659-B4","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMra1405427","article-title":"Latent Mycobacterium tuberculosis infection","volume":"372","author":"Getahun","year":"2015","journal-title":"N Engl J Med"},{"key":"2024032020271949300_ciad659-B5","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMcp2108501","article-title":"Latent tuberculosis infection","volume":"385","author":"Shah","year":"2021","journal-title":"N Engl J Med"},{"key":"2024032020271949300_ciad659-B6","volume-title":"Global tuberculosis report 2022","author":"World Health Organization","year":"2022"},{"key":"2024032020271949300_ciad659-B7","author":"World Health Organization","year":"2020"},{"key":"2024032020271949300_ciad659-B8","author":"World Health Organization","year":"2014"},{"key":"2024032020271949300_ciad659-B9","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","article-title":"The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis","volume":"16","author":"Alsdurf","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2024032020271949300_ciad659-B10","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/cid\/ciac248","article-title":"Evaluation of the latent tuberculosis care cascade among public health clinics in the United States","volume":"75","author":"Holzman","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024032020271949300_ciad659-B11","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/aje\/kwz172","article-title":"Seventy years of tuberculosis prevention: efficacy, effectiveness, toxicity, durability, and duration","volume":"188","author":"Salazar-Austin","year":"2019","journal-title":"Am J Epidemiol"},{"key":"2024032020271949300_ciad659-B12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection","volume":"365","author":"Martinson","year":"2011","journal-title":"N Engl J Med"},{"key":"2024032020271949300_ciad659-B13","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2024032020271949300_ciad659-B14","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"2024032020271949300_ciad659-B15","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"2024032020271949300_ciad659-B16","author":"Chorba"},{"key":"2024032020271949300_ciad659-B17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"2024032020271949300_ciad659-B18","author":"Swindells","year":"2018"},{"key":"2024032020271949300_ciad659-B19","author":"Department of Health and Human Services","year":"2023"},{"key":"2024032020271949300_ciad659-B20","volume-title":"WHO global lists of high burden countries for tuberculosis (TB), TB\/HIV and multidrug\/rifampicin-resistant TB (MDR\/RR-TB), 2021\u20132025","author":"World Health Organization","year":"2021"},{"key":"2024032020271949300_ciad659-B21","first-page":"401","article-title":"Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis","volume":"111","author":"Alfaro E","year":"1998","journal-title":"Med Clin (Barc)"},{"key":"2024032020271949300_ciad659-B22","first-page":"300","article-title":"Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial","volume":"25","author":"Geijo","year":"2007","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2024032020271949300_ciad659-B23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5588\/ijtld.12.0510","article-title":"Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population","volume":"17","author":"Jimenez-Fuentes","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024032020271949300_ciad659-B24","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med"},{"key":"2024032020271949300_ciad659-B25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.15585\/mmwr.mm7108a1","article-title":"Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis\u2014United States, 2022","volume":"71","author":"Carr","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024032020271949300_ciad659-B26","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"2024032020271949300_ciad659-B27","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"2024032020271949300_ciad659-B28","author":"US Food and Drug Administration"},{"key":"2024032020271949300_ciad659-B29","author":"Centers for Disease Control and Prevention","year":"2023"},{"key":"2024032020271949300_ciad659-B30","author":"ClinicalTrials.gov","year":"2021"},{"key":"2024032020271949300_ciad659-B31","author":"ClinicalTrials.gov","year":"2021"},{"key":"2024032020271949300_ciad659-B32","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S2352-4642(21)00052-3","article-title":"Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study","volume":"5","author":"Malik","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"2024032020271949300_ciad659-B33","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1507198","article-title":"A trial of early antiretrovirals and isoniazid preventive therapy in Africa","volume":"373","author":"TEMPRANO ANRS 12136 Study Group","year":"2015","journal-title":"N Engl J Med"},{"key":"2024032020271949300_ciad659-B34","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/506432","article-title":"Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values","volume":"43","author":"Cobelens","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2024032020271949300_ciad659-B35","doi-asserted-by":"crossref","first-page":"e2489","DOI":"10.1371\/journal.pone.0002489","article-title":"The effects of HIV on the sensitivity of a whole blood IFN-gamma release assay in Zambian adults with active tuberculosis","volume":"3","author":"Raby","year":"2008","journal-title":"PLoS One"},{"key":"2024032020271949300_ciad659-B36","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jinf.2020.02.009","article-title":"Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection","volume":"80","author":"Petruccioli","year":"2020","journal-title":"J Infect"},{"key":"2024032020271949300_ciad659-B37","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/cid\/civ464","article-title":"Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention","volume":"61","author":"Podany","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2024032020271949300_ciad659-B38","doi-asserted-by":"crossref","first-page":"e25844","DOI":"10.1002\/jia2.25844","article-title":"Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir\/emtricitabine\/tenofovir alafenamide","volume":"24","author":"Liou","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"2024032020271949300_ciad659-B39","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/S2352-3018(20)30032-1","article-title":"Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1\/2 trial","volume":"7","author":"Dooley","year":"2020","journal-title":"Lancet HIV"},{"key":"2024032020271949300_ciad659-B40","author":"Imperial","year":"2022"},{"key":"2024032020271949300_ciad659-B41","doi-asserted-by":"crossref","first-page":"e22276","DOI":"10.1371\/journal.pone.0022276","article-title":"Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection","volume":"6","author":"Holland","year":"2011","journal-title":"PLoS One"},{"key":"2024032020271949300_ciad659-B42","doi-asserted-by":"crossref","first-page":"e25623","DOI":"10.1002\/jia2.25623","article-title":"Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda","volume":"23","author":"Ferguson","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"2024032020271949300_ciad659-B43","doi-asserted-by":"crossref","first-page":"e1205","DOI":"10.1016\/S2214-109X(23)00251-6","article-title":"Impact and cost-effectiveness of short-course tuberculosis preventive treatment for household contacts and people with HIV in 29 high-incidence countries: a modelling analysis","volume":"11","author":"Ryckman","year":"2023","journal-title":"Lancet Glob Health"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad659\/53480082\/ciad659.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/3\/514\/57037807\/ciad659.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/3\/514\/57037807\/ciad659.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T20:27:57Z","timestamp":1710966477000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/78\/3\/514\/7329955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,10,25]]},"published-print":{"date-parts":[[2024,3,20]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad659","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,15]]},"published":{"date-parts":[[2023,10,25]]}}}